Focus: CryoPort Systems provides temperature-controlled supply chain solutions for biopharmaceuticals across multiple therapeutic areas. Founded in 2024, the company is an early-stage player in the critical but underserved cold-chain logistics market.
Profile data last refreshed 5h ago · AI intelligence enriched 2w ago
Growing — net +6 jobs in 30d
16 jobs added vs 10 removed. Steady team buildout.
CryoPort Systems is a high-risk, high-reward early-stage play suitable only for risk-tolerant professionals willing to bet on supply-chain infrastructure innovation with minimal proof of concept.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for CryoPort Systems
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from CryoPort Systems's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles